Clinical trial NCT02726269 - References

Helicobacter Pylori Gastritis — Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.

Citation(s)

•   Chihu L, Ayala G, Mohar A, Hernández A, Herrera-Goepfert R, Fierros G, González-Márquez H, Silva J
  Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from Mexican adults with clinical outcome. J Chemother. 2005 Jun;17(3):270-6.
•   Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E, Aresti-Zárate S, Hernández M, Pascual EL
  Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012 Sep;67(9):2254-9. doi: 10.1093/jac/dks209. Epub 2012 Jun 11.
•   Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group
  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012 Dec 26;308(24):2594-604. doi: 10.1001/jama.2012.87802.

Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.

Details for clinical trial NCT02726269